Telix Pharmaceuticals (TLX) Notes Payables (2023 - 2026)

Telix Pharmaceuticals (TLX) has reported Notes Payables for 3 consecutive years, with $13.1 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Notes Payables rose 5.57% year-over-year to $13.1 million; the TTM figure through Dec 2025 stood at $13.1 million (up 5.57% YoY), while the FY2025 annual figure was $13.1 million, up 11.45% from the prior year.
• Notes Payables improved to $13.1 million in Q4 2025 per TLX's latest filing, from $12.4 million in the prior quarter.
• Across five years, Notes Payables topped out at $13.1 million in Q4 2025 and bottomed at $627554.8 in Q4 2023.
• Historically, Notes Payables has averaged $8.7 million across 3 years, with a median of $12.4 million in 2024.
• Annual changes were most pronounced in 2024 — Notes Payables jumped 1878.89% — and 2025, when it advanced 5.57%.
• Telix Pharmaceuticals' Notes Payables stood at $627554.8 in 2023, then surged by 1878.89% to $12.4 million in 2024, then grew by 5.57% to $13.1 million in 2025.
• Business Quant data shows TLX's Notes Payables at $13.1 million in Q4 2025, $12.4 million in Q4 2024, and $627554.8 in Q4 2023.